Monday, April 11, 2016

Media Alert: NXT-ID’s (Nasdaq: NXTD) Wocket Smart Wallet Featured in Monthly Computer Chronicles

Wocket Smart Wallet in George Harding’s “What’s New” Feature on CES 2016




Melbourne, FL - April 11, 2016 -- NXT-ID, Inc. (NASDAQ: NXTD), a company focused on the growing mobile commerce market was recently featured in the “What’s New” section of the Monthly Computer Chronicle.

In the article, author George Harding’s coverage of CES 2016 notes that “If you’re like me, you have several credit and debit cards in your wallet or purse. Not only do all the cards make the wallet bulky, but there’s a substantial risk when you travel that losing your wallet will produce disastrous results.
Wocket provides an elegant solution! You can store all your credit and debit cards in this device in a more secure fashion than the cards themselves provide. It’s a bit larger than a credit card and about ¼” thick, so it’s more convenient that than the stuffed wallet.”

He went on to conclude that “This is an interesting technology devised to solve both the crowding we experience today from having so many cards, as well as the security problems associated with magnetic striped cards.”

You can read the full article at http://aztcs.org/reviews/2016-02/2016-02whatsnew.pdf



About Wocket
Wocket® is the smartest wallet you will ever own. Designed to protect your identity and replace your old wallet, simply save your cards into Wocket once and they are immediately secured. You can choose a card from the touch screen and Wocket programs its single, smart card (Wocket Card) or uses its NFC touch to pay technology to match your selection. Your Wocket can be used virtually anywhere that credit cards are accepted today. Wocket can also display a variety of barcodes.

All your credit, debit, loyalty, gift, ID, membership, insurance, medical information, passwords, and virtually any other information can be protected on Wocket®. www.wocketwallet.com

About NXT-ID
NXT-ID is an emerging growth technology company that is focused on products, solutions, and services for security on mobile devices. Our core technologies consist of those that support digital payments, biometric identification, encryption, sensors, and miniaturization. We have three distinct lines of business that we are currently pursuing: mobile commerce, primarily through the application of secure digital payment technologies; biometric access control applications, and Department of Defense contracting. Our initial efforts have primarily focused on the development of our secure products for the growing m-commerce market, most immediately, a secure mobile electronic smart wallet, the Wocket®. The Wocket® is a smart wallet, designed to protect your identity. nxt-id.com; 3d-id.netwocketwallet.com/

Product images are available for media at: http://press.nxt-id.com


Forward-Looking Statements for NXT-ID: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company's business strategy. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Such risks and uncertainties include, among other things, our ability to establish and maintain the proprietary nature of our technology through the patent process, as well as our ability to possibly license from others patents and patent applications necessary to develop products; the availability of financing; the Company's ability to implement its long range business plan for various applications of its technology; the Company's ability to enter into agreements with any necessary marketing and/or distribution partners; the impact of competition, the obtaining and maintenance of any necessary regulatory clearances applicable to applications of the Company's technology; and management of growth and other risks and uncertainties that may be detailed from time to time in the Company's reports filed with the Securities and Exchange Commission.

NXT- ID Inc Contact:
Corporate info: info@nxt-id.com

Media:
D. Van Zant
+1-800-665-0411
press@nxt-id.com

Disclaimer/ Disclosure: The Investorideas.com newswire is a third party publisher of news and research as well as creates original content as a news source. Original content created by investorideas is protected by copyright laws other than syndication rights. Investorideas is a news source on Google news and Linkedintoday plus hundreds of syndication partners. Our site does not make recommendations for purchases or sale of stocks or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated by featured companies, news submissions, content marketing and online advertising. Contact each company directly for press release questions. Disclosure is posted on each release if required but otherwise the news was not compensated for and is published for the sole interest of our readers. Disclosure: As of October 1, 2015 NXT-Id renewed for one year –five thousand per month and fifteen thousand 144 restricted shares for PR, media and marketing. http://www.investorideas.com/About/Disclaimer.asp and http://www.investorideas.com/About/News/Clientspecifics.asp




Friday, April 08, 2016

#Investorideas Updates Global #Stock Directories; Additions for #Mining and #Biotech Stocks

#Investorideas Updates Global #Stock Directories; Additions for #Mining and #Biotech Stocks

(TSX: $KBT.V), (TSX: $KES.V), (NasdaqGM: $ITEK), (NYSE: $GKOS), (NasdaqGM: $AERI) Added

Point Roberts, WA, Delta BC – April 8, 2016 – Investorideas.com, a global news source and investor resource covering leading sectors announces this week’s additions to its global stock directories include mining and biotech stocks.

Companies added in mining: Kaizen Discovery Inc. (TSX: KZD.V), KGHM International Ltd. (Warsaw: KGH), Kombat Copper Inc. (TSX: KBT.V), Kesselrun Resources Ltd. (TSX: KES.V), Khalkos Exploration Inc. (TSX: KAS.V), Kingsgate Consolidated Limited (ASX: KCN.AX), Knick Exploration Inc. (TSX: KNX.V) and Kopy Goldfields AB (NasdaqOMX: KOPY; Stockholm: KOPY.ST).

These companies are exploring in Canada, Russia, Australia, South America, and Africa and are involved in the exploration of gold, copper, silver.

Other additions are as follows:
Biotech:
Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI), Glaukos Corporation (NYSE:GKOS), Inotek Pharmaceuticals Corp. (NasdaqGM:ITEK), NicOx SA (Paris: COX.PA)  and Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC:SNPHY).

The biotech companies added were part of a feature article and research for treatment for glaucoma.  You can read the article in full at http://www.investorideas.com/news/2016/biotech/04071.asp  and learn more about each company.

Investorideas.com features news and stock directories covering mining stocks, biotech stocks, water stocks, renewable energy, tech and other headline investing sectors.  
Coverage includes NASDAQ, TSX, NYSE, OTC and global stock exchanges.

About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com  is a digital news source and investor resource covering leading sectors.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Investor Ideas Directories for global investors:
From water stocks to gold and mining stocks, renewable energy, nanotech, defense, technology, biotech and more – use our stock directories and access them online 24/7 with login as a member to find your next big idea!

Services for Publicly traded companies: http://www.investorideas.com/Investors/Services.asp

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Contact Investorideas.com

800-665-0411

Thursday, April 07, 2016

Nevada Energy Metals’ (TSXV: BFF.V; OTC: SSMLF; Frankfurt: A2AFBV), Advisory Board Member Malcolm Bell, Charged-up on Lithium!

Nevada Energy Metals’ (TSXV: BFF.V; OTC: SSMLF; Frankfurt: A2AFBV)Advisory Board Member Malcolm Bell, Charged-up on Lithium!


These days, investors in emerging lithium companies seem only to care about two things. How close is a property to a producing lithium operation (or basin with high lithium concentrations)? And, how many acres (hectares) is it? Look at Clayton Valley, Nevada, home to Albemarle Corp.’s Silver Peak lithium brine operation.

Conventional wisdom says to be as close to Silver Peak as possible, wielding as many acres as possible. However, newly appointed Technical Advisor Malcolm Bell of Nevada Energy Metals, Inc. (TSX-V: BFF)/ (OTC: SSMLF) / (Frankfurt: A2AFBV), believes there could be other Clayton Valley-like basins in the State. It’s not the zip code that counts most, but the geological setting and volcanic history.

Is it a certainty that Nevada will become a meaningful lithium suppler? No. But consider that an area of great promise for lithium-ion battery demand is the U.S. Department of Defense, (DOD). I mention it to support my view that, “security of supply” will be a crucial factor going forward. Will the DOD (indirectly) continue to rely on countries in South America and CHINA! for critical lithium-ion battery materials? 



If pricing remains stronger for longer, and demand continues to soar, the world will need more lithium, especially from safe, reliable jurisdictions. Companies like Nevada Energy Metals plan to be ready. As a project generator, the Company is well on its way in accumulating a robust portfolio of wholly-owned & JV properties. With Malcolm’s guidance, and the help of new hires (yet to be finalized), the team will have a lot on their plates. In fact, they already do, actively evaluating acquisitions and staking additional promising locations.

On March 22nd, Nevada Energy Metals appointed Mr. J. Malcolm Bell to the Advisory Board and as lead consultant for project acquisitions & land development opportunities.

Mr. Bell has over 45 years of resource industry experience either as principal, director, or senior officer of private & public companies. In 1980, he founded Hi-Tec Resource Management Ltd., a successful minerals exploration company. In 1986, he founded the International Investment & Business Opportunities Exposition, the first investment trade show company in Canada. 

In 1997, he co-founded British Canadian Mines Ltd., containing the largest privately held mineral exploration portfolio in Newfoundland; and subsequently completed a $13-million reverse merger on it. In 2002, he helped negotiate a $20-million merger between Olympic Resources Ltd & Whittier Energy Corp. Currently, Mr. Bell heads a private Vancouver-based consultancy that sources projects & capital for companies engaged in mining, renewable energy & technology ventures. 

I, Peter Epstein, CFA, MBA, caught up with Malcolm in the week ended April 1st to ask him a few questions. We spoke at length about his background and what he brings to the table. Mostly, he explained how nature has endowed Nevada with ideal conditions that, in select places, allow lithium to become concentrated in clays and brines.  

Your extensive experience in natural resources, including sourcing projects & capital, affords you opportunities to serve in advisory roles for many Nevada juniors. Why choose lithium, and why Nevada Energy Metals, Inc.? 

Nevada is an area of strong interest for me. At times it’s been for gold or copper, but now my focus is on lithium and its strategic importance. For months before joining the Technical Board, I was working closely with the Company on identifying and locking down lithium-bearing properties and staking ground. I helped them with the 100% acquisition of Teels Marsh West and with their option agreement on up to 60% of Alkali Lake.

 I’m very bullish on lithium demand and Nevada’s potential role in supplying it.



Regarding Nevada Energy Metals, I’m excited by the pace, the speed at which things are getting done. In addition to the two transactions mentioned, I helped successfully stake a very promising property in the San Emidio Desert basin. On top of that, the Company is already starting (next week) a phase 1 exploration program on Teels Marsh West

So, this is a company that wants to advance properties, not just sit on them. Regarding other lithium juniors, I think that I can add the most value here, by spearheading an aggressive property acquisition mandate. The Nevada Energy Metals has a lot of irons in the fire, the next few months should be a very active time for both the Company and me!  

You and Nevada Energy Metals are not alone in being bullish on lithium prospects in the State. What about the climate / geology of Nevada fostered the deposition of lithium in brines? 

That’s a great question. Dry desert-like climatic conditions and a favorable geological environment created conditions, over hundreds of thousands of years, that are today prospective for lithium in clays and lithium in brine deposits. There are four main reasons.  

Firstly, it’s generally recognized that undrained, or closed desert playa basins are the most prospective locations. Secondly, there should be a history of large-scale volcanic eruptions, contributing large volumes of volcanic ash, containing trace amounts of lithium into the basin. Thirdly, the basin should sit atop, or be in very close proximity to, a geothermal heat source and hot springs.

Finally, there needs to be (or have been) an inflow of lithium-bearing hot spring fluids into the closed basin over a very long period, to boost the lithium content of existing brines. Most important, the same heat source responsible for the hot springs, has to have created a hot water convection cycle. This hot water convection cycle is what ties it all together. Only a trace amount of lithium is in the hot water, BUT over thousands of years the convection cycle deposits lithium into the basin over and over and over again…. The continuous hot springs cycling allows lithium concentrations to build. 

Can you tell us about the staking of the San Emidio Desert basin?

Yes, the staking of 86 placer claims covering about 1,700 acres was announced last week. The property is about 60 miles (95 km) northeast of Reno, fairly close to where Tesla is building its giga-factory. The San Emidio Desert basin is an alkali playa environment being fed by lithium-bearing geothermal fluids. 



All of the criteria I described earlier is present at San Emidio. To be clear, this does not ensure that favorable brine concentrations will be found. But it shows it’s a promising target to explore and test for a commercial deposit. Given the limited exploration for lithium in Nevada to date, there certainly could be another Clayton Valley-like discovery. If the right conditions are in place, robust lithium brine deposits could be at large.

Can you please explain the initial phase of exploration at Teels Marsh West, and what you hope to accomplish?

Yes, we’re excited to start a surface exploration program on Teels Marsh West next week. The marsh covers roughly 2,000 acres (~810 hectares) in Mineral County. Lithium concentrations at Teels Marsh of up to 850 ppm were reported in sampling programs conducted by the US Geological Survey (OFR: 76-567).

The initial exploration phase consists of 20 shallow holes designed to collect fluid and sediment samples situated nearby a previously discovered thermal area. The area is on, and adjacent to, a range front fault system along the west side of the marsh. Close proximity to a geothermal heat source is believed to be a principal requirement for concentrating lithium in the brines at Clayton Valley.

Finding lithium concentrations is all fine and good, but the parts per million (ppm) are lower than the brines found in Argentina & Chile, why should anyone care about Nevada? 

I’m no expert in lithium fundamentals or pricing, but the only North American producing mine, Silver Peak, is thought to be concentrating brines with initial lithium values of 150ppm to 250ppm. That’s using the decades old technology / process of solar evaporation. Most geologists believe that closed basins in places like Clayton Valley would be able to produce average concentrations of at least 200ppm.

Right, 200ppm is less than South American lithium values, but Nevada is ground zero of several new processing technologies that have potential to be superior to harvesting brines in giant evaporation ponds. To be clear, these technologies are mostly in scale-up phase. Still, most lithium juniors around the world are several years from commercial production, leaving plenty of time for new technologies to catch up.  

Thank you Malcolm for your time and insightful answers to my questions. Good luck in your new role at Nevada Energy Metals.

For more information, about Nevada Energy Metals:

Trading Symbols: TSX-V: BFF  OTC Markets: SSMLF Frankfurt/Xetra: A2AFBV


(Article/interview of Malcolm Bell, Technical Advisor of Nevada Energy Metals, for InvestorIdeas.com)
Contact Info: Peter Epstein
845-304-7386

Disclosures: Readers are charged with conducting their own investment due diligence and recognize that small cap stocks can deliver a 100% loss of investment capital. The author or interviewer as the case may be, Peter Epstein, CFA, MBA, believes that he’s diligent and prudent in screening out companies that, for any reasons whatsoever, are unattractive investment opportunities. However, he cannot guarantee that his efforts will be successful. Readers understand that Mr. Epstein cannot be held accountable or responsible for the accuracy of opinions, facts, estimates, forecasts and assumptions conveyed herein or for investment actions taken by readers.

At the time this interview was published, Nevada Energy Metals was a sponsor of EpsteinResearch.com. Mr. Epstein owns stock in the Company. He is not a registered or licensed financial advisor. His article(s) on Nevada Energy Metals and other small cap companies should be considered very carefully in this context. Readers are urged to consult with their own financial advisors before making investment decisions. This company, and all small cap companies, are highly speculative, not suitable for all investors. 

Any commentary suggesting that a particular stock is, “under valued,” “over-sold,” a “compelling opportunity,” is “de-risked,” could be “re-rated,” or similar words and phrases, are not directed at any individual or group and do not constitute investment advice. Each individual and group must make their own determination regarding the suitability of any stock mentioned herein. Any comparisons between or among stocks are for illustrative purposes only and are not be taken as fact or relied upon. Nothing herein is to be considered explicitly or implicitly a part of full and proper due diligence.

This interview and does not constitute an offer or a solicitation of an offer for the purchase or sale of any shares or other securities of the companies referred to herein.  There are substantial risks associated with investing in development stage exploration companies.  Potential investors should seek advice from a qualified financial dealer prior to investing in any company referred to herein.  No securities commission or similar authority has in any way passed on any of the information contained in this interview.


This news is published on the Investorideas.com Newswire - a global digital news source for investors and business leaders
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published/created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.


Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with a Variety of Treatments

Glaucoma Companies Aerie (Nasdaq:AERI), Glaukos (NYSE:GKOS), Q BioMed (OTCQB:QBIO), Inotek (Nasdaq:ITEK), NicOx SA (Paris: COX.PA) Approach a Devasting Disease with  a Variety of Treatments

New York, NY; Pt, Roberts, WA - April 7, 2016- Investorideas.com, a digital global news source covering leading sectors including medical technology and biotech stocks releases the following report on Glaucoma and public companies currently involved in the treatment of the disease. Glaucoma is a group of eye diseases which result in damage to the eye’s optic nerve and left untreated will lead to vision loss and eventual blindness.

US Companies currently working on Glaucoma treatments include Q BioMed Inc, (QBIO), Aerie Pharmaceuticals (AERI), Glaukos Corporation (GKOS), Inotek (ITEK).

Internationally, NicOx SA (Paris: COX.PA) and Santen Pharmaceuticals Co. Ltd. (Tokyo:4536) are leading the way with research and development and treatment options for the disease.


Company News:
On March 28, Aerie Pharmaceuticals (NasdaqGM:AERI) issued a press release announcing the that dosing commenced of the first patients enrolled in Mercury 2, the Company’s second Phase 3 registration trial of Roclatan(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, a novel once-daily eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

The same day, Glaukos Corporation (NYSE:GKOS) announced that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved its iStent® Trabecular Micro-Bypass Stent for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients diagnosed with mild to moderate open-angle glaucoma who are currently treated with ocular hypotensive medication. The iStent is the first-ever ab interno Micro-Invasive Glaucoma Surgery (MIGS) device approved for use in Japan.



Q BioMed Inc, (OTCQB:QBIO) expanded on the company’s Corporate Update with a Q&A with Investorideas.com and a video interview with StockNewsNow was also released.

In both interviews, President Denis Corin included the Mannin Research Inc. license agreement and the glaucoma eye drop treatment being developed by Dr. Susan Quaggin.  Mannin Research’s (Mannin) Glaucoma therapeutic is a first-in-class therapeutic designed to treat Primary Open-Angle Glaucoma. It is based on the research by Dr. Susan Quaggin, Director of the Feinberg Cardiovascular Research Institute and Chief of the Division of Nephrology and Hypertension at Northwestern University. The MAN-01 therapeutic is an important molecule in the context of new pharmaceuticals that can treat Glaucoma. Mannin’s therapeutic will address increased intraocular pressure in the eye by acting on a vessel in the eye called the Schlemm’s Canal, which is a main drainage path for the eye. Mannin is currently in the pre-clinical phase. Optimizing the molecule, the aim is to use it in the clinic in late 2017/early 2018.

In early March, Inotech Pharmaceutical Corporation (NasdaqGM: ITEK) announced that it had strengthened the Patent Estate for its lead drug candidate Trabodenoson, an investigational agent currently in pivotal Phase 3 clinical trials for the treatment of glaucoma.

In late February, NicOx SA (Paris: COX.PA) provided a corporate update which included a report on its US FDA review for an IOP (intraocular pressure) lowering singe-agent eye drop for patients with open-angle glaucoma

Santen Pharmaceuticals Co. Ltd. (Tokyo:4536.T; OTC: SNPHY) is focused on corneal disorders that lack effective treatment options and on glaucoma and retinal disorders that are increasing in prevalence due to the aging of society.

Novartis AG (NYSE:NVS) subsidiary Alcon, the global leader in eye care and a division of Novartis released news in February of 2016 announcing that it had entered into an agreement to acquire Transcend Medical, Inc., a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma.

Pfizer Inc’s (NYSE:PFE) Ophthalmology Unit indicates that it is interested in “establishing alliances to develop therapeutics, expand disease biology understanding, and identify biomarkers” in a number of ophthalmological areas including glaucoma.

Acadia Pharmaceuticals Inc.’s (NasdaqGS:ACAD) Muscarinic Program have discovered small-molecule product candidates for the treatment of glaucoma. Using a proprietary discovery platform, they identified a subtype of the muscarinic receptors that controls intraocular pressure and discovered lead compounds that selectively activate this target. 


The Market Outlook:
The global glaucoma surgical devices market is expected to reach USD 3.11 billion by 2020, growing at a CAGR of close to 41%, according to Technavio’s latest report.

TechNavio's analysts forecast the Global Glaucoma Therapeutics market will grow at a CAGR of 2.53 percent over the period 2013-2018.

TechNavio's analysts forecast the Global Glaucoma Devices market to grow at a CAGR of 20.72 percent over the period 2013-2018.



About Q BioMed Inc. (OTCQB:QBIO):
Q BioMed Inc. ("Q") is a biomedical acceleration and development company. We are focused on acquiring companies and biomedical assets. Q is dedicated to providing these target companies and assets, strategic resources, developmental support, and expansion capital to ensure they meet their developmental potential enabling them to provide products to patients in need.

About Aerie Pharmaceuticals, Inc. (NasdaqGM:AERI):
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. Aerie's two lead product candidates are once-daiIy IOP-lowering therapies with novel mechanisms of action to treat patients with glaucoma and ocular hypertension. It is expected that the NDA filing for Rhopressa (netarsudil ophthalmic solution) 0.02% will take place in the third quarter of 2016. The second product candidate, Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a fixed dose combination of Rhopressa and widely prescribed PGA latanoprost, currently has two Phase 3 registration trials underway, named Mercury 1 and Mercury 2. If these trials are successful, a Roclatan NDA filing is expected to take place in the second half of 2017. In addition, Aerie is further building its pipeline, including through research collaborations with GrayBug, Inc. and Ramot at Tel Aviv University.  http://www.aeriepharma.com/

About Glaukos (NYSE:GKOS):
Glaukos is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures to transform the treatment of glaucoma, one of the world’s leading causes of blindness. The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm. Glaukos launched the iStent® its first MIGS device, in the United States in July 2012 and is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression. http://www.glaukos.com/

About Inotek Pharmaceuticals Corp. (NasdaqGM:ITEK):
Inotek  is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company's lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development Trabodenoson was developed in Inotek's laboratories and is designed to restore the eye's natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. http://www.inotekpharma.com/

About NicOx SA (Paris: COX.PA):
NicOx is an international commercial-stage company focused on the ophthalmic market. With a heritage of innovative R&D, business development and marketing expertise, Nicox is building a diversified portfolio of ophthalmic products that can help people enhance their sight. Nicox's advanced pipeline features latanoprostene bunod for the lowering of intra-ocular pressure (IOP) in patients with open angle glaucoma or ocular hypertension, and for which a New Drug Application (NDA) was submitted to the FDA by the Company's licensee Valeant. The Company's pipeline also features AC-170, a pre-NDA candidate for the treatment of ocular itching associated with allergic conjunctivitis, as well as two pre-MAA candidates in Europe: AzaSite® for bacterial conjunctivitis and BromSite(TM) for pain and inflammation after cataract surgery. Beyond these late-stage candidates, Nicox is developing a pipeline of next generation ophthalmology-focused candidates which utilize its proprietary nitric oxide (NO)-donating research platform. The Group has operations in Europe and the United States.
About Investorideas.com - Big Ideas for Global Investors
InvestorIdeas.com - digital media global news source, PR and social media in leading sectors.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Sign up for free news alerts at Investorideas.com
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Disclosure: QBIO has retained investorideas.com for PR, media, news publication and social media effective February 5th for three months: two thousand five hundred per month.

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Contact Investorideas.com
800 665 0411